- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.12.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.11.24 | Inhibikase Therapeutics files for secondary offering of common stock | 3 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 | 2 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 158 | GlobeNewswire (Europe) | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
| 14.11.24 | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.10.24 | Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More | 45 | Insider Monkey | ||
| 22.10.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10.24 | Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | 162 | GlobeNewswire (Europe) | -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and... ► Artikel lesen | |
| 14.10.24 | H.C. Wainwright senkt Kursziel für Inhibikase Therapeutics; behält Kaufempfehlung bei | 3 | Investing.com Deutsch | ||
| 14.10.24 | Inhibikase Therapeutics stock target cut by H.C. Wainwright; retains Buy rating | 1 | Investing.com | ||
| 09.10.24 | Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today | 1 | Benzinga.com | ||
| 09.10.24 | Inhibikase Therapeutics stock rises after pricing $110M private offering | 2 | Seeking Alpha | ||
| 09.10.24 | Inhibikase Therapeutics announces $110 million financing | 2 | Investing.com | ||
| 09.10.24 | Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension | 2 | GlobeNewswire (USA) | ||
| 09.10.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 16.08.24 | Inhibikase shares target cut, analyst retains buy rating on earnings report | 2 | Investing.com | ||
| 16.08.24 | Earnings call: Inhibikase Therapeutics reports Q2 financials, trial updates | 3 | Investing.com | ||
| 15.08.24 | Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01 | 1 | Seeking Alpha | ||
| 14.08.24 | Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity | 112 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 167,88 | -0,58 % | AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology | WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets... ► Artikel lesen | |
| TEVA | 20,500 | -1,44 % | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab) | REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,980 | +4,29 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| BAUSCH HEALTH | 7,406 | +0,03 % | Bausch Health Companies Inc.: Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025 | LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February... ► Artikel lesen | |
| ORGANIGRAM | 1,488 | +4,06 % | OrganiGram-Aktie: Warum Anleger jetzt genau hinschauen sollten | Im Schatten von Branchenriesen wie Tilray und Canopy Growth zeigt die Aktie des kanadischen Cannabis-Unternehmens OrganiGram in den letzten 4 Wochen klare Aufwärtstendenzen - und das nicht ohne Grund.... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,840 | 0,00 % | Quantum Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ASTRIA THERAPEUTICS | 7,500 | -0,53 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 119,05 | +0,29 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,892 | -1,33 % | XORTX Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| MADRIGAL PHARMACEUTICALS | 310,30 | +4,58 % | Verkaufsleiterin von Madrigal Pharmaceuticals veräußert Aktien im Wert von 116.328 US-Dollar | ||
| BRIDGEBIO PHARMA | 34,780 | -0,51 % | Why BridgeBio Pharma (BBIO) Is Skyrocketing Now | ||
| VERONA PHARMA PLC ADR | 51,00 | -0,97 % | Verona Pharma ADR Aktie: Eine neue Wachstumsphase | Die Verona Pharma ADR verzeichnet eine positive Entwicklung an den Börsen. Der Aktienkurs des biopharmazeutischen Unternehmens erreichte am 25. Januar 2025 einen Stand von 52,50 EUR, was einer bemerkenswerten... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,084 | -9,68 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 1,142 | +4,58 % | Opus Genetics, Inc. - 8-K, Current Report | ||
| RIGEL PHARMACEUTICALS | 20,400 | -1,92 % | Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 2,740 Euro und damit -0,36 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.
